Spots Global Cancer Trial Database for carcinoma, transitional cell
Every month we try and update this database with for carcinoma, transitional cell cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study | NCT02793128 | Carcinoma, Tran... Transitional Ce... | UGN-101 instill... | 18 Years - | UroGen Pharma Ltd. | |
| uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto | NCT05874921 | Urothelial Carc... Urothelial Carc... Urothelial Carc... Urothelial Carc... Urothelial Canc... Urothelial Carc... Carcinoma, Tran... Transitional Ce... | Jelmyto (mitomy... | 18 Years - | UroGen Pharma Ltd. | |
| Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | NCT02014337 | Breast Cancer Ovarian Epithel... Sarcoma Non-small Cell ... Carcinoma, Tran... Prostate Cancer Prostatic Neopl... | Mifepristone an... | 18 Years - | Corcept Therapeutics | |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | NCT04660929 | HER2-positive Adenocarcinoma Bile Duct Cance... Biliary Tract C... Bladder Cancer Breast Cancer Breast Neoplasm Carcinoma, Duct... Carcinoma, Hepa... Cancer Lung Cancer, No... Carcinoma, Ovar... Carcinoma, Smal... Carcinoma, Squa... Carcinoma, Tran... Colorectal Canc... Esophagogastric... Inflammatory Br... Stomach Neoplas... Malignant Neopl... Ovarian Neoplas... Pancreatic Canc... HER2-positive S... HER2-positive B... HER2-positive G... HER-2 Protein O... HER-2 Gene Ampl... Prostate Cancer Head and Neck C... Endometrial Can... Lung Cancer, Sm... | CT-0508 Pembrolizumab | 18 Years - | Carisma Therapeutics Inc | |
| A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma | NCT05318339 | Carcinoma, Tran... HER-2 Gene Ampl... | Trastuzumab | 18 Years - | ChineseAMS | |
| TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium | NCT00077688 | Bladder Neoplas... Ureteral Neopla... Urethral Neopla... Carcinoma, Tran... | TOCOSOL Paclita... | 18 Years - | Achieve Life Sciences | |
| 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen | NCT00191971 | Urologic Neopla... Carcinoma, Tran... | Gemcitabine | 20 Years - 74 Years | Eli Lilly and Company | |
| Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder | NCT00722553 | Carcinoma, Tran... Bladder Cancer Bladder Neoplas... | Pralatrexate In... Vitamin B12 Folic Acid | 18 Years - | Acrotech Biopharma Inc. | |
| Neoadjuvant Atezolizumab in Localized Bladder Cancer | NCT02451423 | Carcinoma, Tran... | Atezolizumab | 18 Years - | University of California, San Francisco | |
| Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer | NCT04039867 | Carcinoma, Tran... | Oxaliplatin wit... | 18 Years - | University of California, Irvine | |
| Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer | NCT04039867 | Carcinoma, Tran... | Oxaliplatin wit... | 18 Years - | University of California, Irvine | |
| A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection | NCT02450331 | Carcinoma, Tran... | Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer | NCT02300610 | Bladder Cancer Carcinoma, Tran... Renal Pelvis Ca... Ureter Cancer Urethra Cancer | Enzalutamide Cisplatin Gemcitabine | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer | NCT01529411 | Carcinoma, Tran... | Vinflunine Undefined (stan... | 18 Years - 80 Years | Spanish Oncology Genito-Urinary Group | |
| Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | NCT02014337 | Breast Cancer Ovarian Epithel... Sarcoma Non-small Cell ... Carcinoma, Tran... Prostate Cancer Prostatic Neopl... | Mifepristone an... | 18 Years - | Corcept Therapeutics | |
| Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer | NCT00101842 | Carcinoma, Tran... | Pemetrexed Gemcitabine Platinol | 18 Years - | Eli Lilly and Company | |
| Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer | NCT04039867 | Carcinoma, Tran... | Oxaliplatin wit... | 18 Years - | University of California, Irvine | |
| Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma | NCT00172367 | Carcinoma, Tran... | Lycopene | 18 Years - | National Taiwan University Hospital | |
| Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma | NCT03410693 | Carcinoma, Tran... | Rogaratinib (BA... Chemotherapy | 18 Years - | Bayer | |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | NCT04660929 | HER2-positive Adenocarcinoma Bile Duct Cance... Biliary Tract C... Bladder Cancer Breast Cancer Breast Neoplasm Carcinoma, Duct... Carcinoma, Hepa... Cancer Lung Cancer, No... Carcinoma, Ovar... Carcinoma, Smal... Carcinoma, Squa... Carcinoma, Tran... Colorectal Canc... Esophagogastric... Inflammatory Br... Stomach Neoplas... Malignant Neopl... Ovarian Neoplas... Pancreatic Canc... HER2-positive S... HER2-positive B... HER2-positive G... HER-2 Protein O... HER-2 Gene Ampl... Prostate Cancer Head and Neck C... Endometrial Can... Lung Cancer, Sm... | CT-0508 Pembrolizumab | 18 Years - | Carisma Therapeutics Inc | |
| A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer | NCT03288545 | Carcinoma, Tran... Urinary Bladder... Urologic Neopla... Renal Pelvis Ne... Urothelial Canc... Ureteral Neopla... Urethral Neopla... | enfortumab vedo... pembrolizumab cisplatin carboplatin gemcitabine | 18 Years - | Astellas Pharma Inc | |
| Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma | NCT00172367 | Carcinoma, Tran... | Lycopene | 18 Years - | National Taiwan University Hospital | |
| A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma | NCT05318339 | Carcinoma, Tran... HER-2 Gene Ampl... | Trastuzumab | 18 Years - | ChineseAMS | |
| Tesetaxel for Previously Treated Patients With Bladder Cancer | NCT01215877 | Carcinoma, Tran... | Tesetaxel | 18 Years - | Genta Incorporated | |
| Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer | NCT00146276 | Bladder Cancer Carcinoma, Tran... | gemcitabine | 18 Years - | Association of Urologic Oncology (AUO) | |
| The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study | NCT02793128 | Carcinoma, Tran... Transitional Ce... | UGN-101 instill... | 18 Years - | UroGen Pharma Ltd. | |
| Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer | NCT01529411 | Carcinoma, Tran... | Vinflunine Undefined (stan... | 18 Years - 80 Years | Spanish Oncology Genito-Urinary Group | |
| Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract | NCT03051373 | Carcinoma, Tran... | nanoparticle al... Gemcitabine, ci... | 18 Years - 70 Years | Chinese PLA General Hospital | |
| Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder | NCT00722553 | Carcinoma, Tran... Bladder Cancer Bladder Neoplas... | Pralatrexate In... Vitamin B12 Folic Acid | 18 Years - | Acrotech Biopharma Inc. | |
| Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer | NCT02300610 | Bladder Cancer Carcinoma, Tran... Renal Pelvis Ca... Ureter Cancer Urethra Cancer | Enzalutamide Cisplatin Gemcitabine | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors | NCT01478685 | Urinary Bladder... Carcinoma, Tran... Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... Carcinoma, Non-... Carcinoma, Panc... Tumor Virus Inf... | CC-486 Carboplatin ABI-007 | 18 Years - | Celgene | |
| A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors | NCT01478685 | Urinary Bladder... Carcinoma, Tran... Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... Carcinoma, Non-... Carcinoma, Panc... Tumor Virus Inf... | CC-486 Carboplatin ABI-007 | 18 Years - | Celgene | |
| A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma | NCT05318339 | Carcinoma, Tran... HER-2 Gene Ampl... | Trastuzumab | 18 Years - | ChineseAMS |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
